Natco Pharma has received a demand notice from the National Pharmaceutical Pricing Authority for ₹4.92 crore. The notice relates to alleged overcharging on two specific drugs during the period from April 2023 to November 2023. The company has clarified that this development will not have any material impact on its overall financial, operational, or other business activities.
Details of the Demand Notice
On May 12, 2026, Natco Pharma was served a demand notice concerning pricing compliance for two of its pharmaceutical products. The authorities have directed the company to deposit a total amount of ₹4,92,25,923. This figure represents the sum of the alleged overcharged amounts, along with applicable penalties and interest accrued.
Impact Assessment
The company has evaluated the potential repercussions of this notice on its business operations. According to the official statement, there is no material impact expected on the financial position, day-to-day operations, or other strategic activities of the company. Natco Pharma remains committed to addressing the requirements set forth by the authority.
Clarification on Disclosure Timing
The company acknowledged a delay in reporting this development to the stock exchanges. This was attributed to technical issues and procedural delays in the internal flow of information. Natco Pharma has now completed the necessary filings and has committed to implementing improved measures to prevent similar reporting delays in the future.
Source: BSE
